StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SUDARSHAN.BO$34.08-0.79%
Fair $34.08+0.0%

SUDARSHAN.BO

Sudarshan Pharma Industries Limited

Basic Materials / ChemicalsBSE

$34.08

-0.27 (-0.79%)

Fairly Valued+0.0%Fair Value $34.08Fund rank 21/100 · Data gapFallback financials|
SA 51/C
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-535.7M · quality 39.7/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 19/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

51/100

C

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · SUDARSHAN.BOLocal privado en este navegador · Sudarshan Pharma Industries Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$8.2B

P/E

35.1x

↑

EV/EBITDA

18.4x

↑

ROE

14.9%

↑

Gross Margin

11.9%

↓

Debt/Equity

1.82

↑
52-Week Range$34
$19$37

TradingView lightweight chart

SUDARSHAN.BO price, volumen y niveles de valoración

Último $34.08Periodo -50.9%
Fair value: $34.08

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+15.1%

FCF CAGR

—

FCF margin

-10.2%

FCF / Net income

-3.06x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.03B · net income $233.0M · FCF $-714.0M

2023-FY → 2026-FY

Gross margin

11.9%+5.5% pts

Operating margin

6.8%+3.6% pts

Net margin

3.3%+1.8% pts

FCF margin

-10.2%-0.9% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$7.03B$7.03B$5.05B$4.64B$4.61B
Net Income$233.0M$233.0M$149.7M$114.6M$70.4M
EBITDA$600.3M$600.3M$388.7M$243.4M$149.9M
EPS0.970.970.620.470.55
Gross Margin11.9%11.9%12.9%8.7%6.4%
Operating Margin6.8%6.8%7.2%4.7%3.1%
Net Margin3.3%3.3%3.0%2.5%1.5%
Balance Sheet
Debt/Equity1.821.821.300.940.34
Current Ratio1.071.07———
Cash Flow
Free Cash Flow$-714.0M$-714.0M$-535.7M$39.7M$-426.0M
Returns
ROE14.9%14.9%11.4%10.3%7.0%
Valuation
P/E35.1335.1350.58170.53106.72
EV/EBITDA18.3718.3723.8612.2251.63
P/B5.245.245.761.737.44
Growth & Yield
Revenue Growth39.2%39.2%9.0%0.5%—
EPS Growth56.5%56.5%31.9%-14.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

46.1%

muy exigente

EPS terminal req.

$3.02

Spread vs growth

10.4%

5Y implied EPS CAGR

30.4%

muy exigente

EPS terminal req.

$3.66

Spread vs growth

26.0%

10Y implied EPS CAGR

19.8%

exigente

EPS terminal req.

$5.89

Spread vs growth

36.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.0%

Total return

+7.0%

Start / end P/E

51.4x → 35.1x

EPS bridge

0.62 → 0.97

Residual

-17.8%

EPS growth+56.5%
Multiple rerating-31.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term-17.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.